Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Depreciation & Amortization (CF): 2021-2025

Historic Depreciation & Amortization (CF) for Amylyx Pharmaceuticals (AMLX) over the last 5 years, with Sep 2025 value amounting to $100,000.

  • Amylyx Pharmaceuticals' Depreciation & Amortization (CF) fell 50.00% to $100,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $600,000, marking a year-over-year decrease of 40.06%. This contributed to the annual value of $900,000 for FY2024, which is 18.18% down from last year.
  • Latest data reveals that Amylyx Pharmaceuticals reported Depreciation & Amortization (CF) of $100,000 as of Q3 2025, which was down 0.00% from $100,000 recorded in Q2 2025.
  • In the past 5 years, Amylyx Pharmaceuticals' Depreciation & Amortization (CF) registered a high of $302,000 during Q3 2023, and its lowest value of $10,000 during Q1 2021.
  • Its 3-year average for Depreciation & Amortization (CF) is $217,091, with a median of $200,000 in 2025.
  • Per our database at Business Quant, Amylyx Pharmaceuticals' Depreciation & Amortization (CF) spiked by 1,550.00% in 2022 and then slumped by 50.00% in 2025.
  • Amylyx Pharmaceuticals' Depreciation & Amortization (CF) (Quarterly) stood at $22,000 in 2021, then surged by 727.27% to $182,000 in 2022, then surged by 65.38% to $301,000 in 2023, then plummeted by 33.55% to $200,000 in 2024, then slumped by 50.00% to $100,000 in 2025.
  • Its Depreciation & Amortization (CF) was $100,000 in Q3 2025, compared to $100,000 in Q2 2025 and $200,000 in Q1 2025.